Earnings call
Indoco Remedies Q3 FY25 earnings call: Indoco Remedies Limited expects Europe to grow close to 15% at least; the company said it was not giving much guidance
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company expects Europe to grow close to 15% at least; the company said it was not giving much guidance. At Indoco Remedies Limited's Plant II sterile plant, Line 1 was fully operational and had exported one terminally sterilized product to the US; Line 2 was operational and taking exhibit batches but had not been inspected by the FDA. Cyclopam, Indoco Remedies Limited's largest brand on the MAC basis in IQVIA, was at INR175 crores and grew by more than 20% at the time of the call. Indoco Remedies' prescriptions for Oxipod-CV are growing by 40%.
The numbers management gave
Results
- Cyclopam, Indoco Remedies Limited's largest brand on the MAC basis in IQVIA, was at INR175 crores and grew by more than 20% at the time of the call.
Show source
Cyclopam, the largest brand of the company on the MAC basis in IQVIA today is at INR175 crores with a growth in excess of 20%.
- New introductions formed 4.8% of Indoco Remedies Limited's top line, compared with the industry benchmark of 2.8%.
Show source
New introductions now form 4.8% of top line vis-a-vis the industry benchmark of 2.8%.
- Supplies of Indoco Remedies Limited's finished formulations to regulated markets in the US and EU were severely affected in the third quarter of financial year 2025, partly because of corrections being implemented at facilities under the master manufacturing plan and largely because of the FDA warning letter for Plant II, the sterile plant in Goa.
Show source
As I said in the beginning, most of our issues have been on the supply side, and supplies of finished formulations to the regulated markets for both US and EU have been severely affected in this quarter.
- Standalone net revenues in the third quarter of financial year 2025 were INR3,649 million, compared with INR4,484 million in the same quarter last year.
Show source
Net revenues of the company for the third quarter FY '24-'25 are at INR3,649 million compared to INR4,484 million for the same quarter last year.
- Standalone EBITDA to net sales in the third quarter of financial year 2025 was 5.5% at INR201 million, compared with 14.6% at INR653 million in the same quarter last year.
Show source
EBITDA to net sales for the quarter is 5.5% at INR201 million compared to 14.6% at INR653 million.
- Domestic formulation business revenue grew by 5.5% to INR2,242 million in the third quarter of financial year 2025, compared with INR2,126 million in the same quarter last year.
Show source
The domestic formulation business, revenues from this business for the quarter grew by 5.5% at INR2,242 million as compared to INR2,126 million.
Show 20 more statements
Results
- Vitamins, Minerals, Nutrients; Cardiac; Urology; and Gastrointestinal therapeutic segments performed well in the third quarter of financial year 2025 compared with the same quarter last year.
Show source
Major therapeutic segments, namely Vitamins, Minerals, Nutrients; Cardiac; Urology; and Gastrointestinal performed well during the quarter as compared to the same quarter last year.
- International business revenue was INR1,074 million in the third quarter of financial year 2025, compared with INR1,947 million in the same quarter last year.
Show source
Page 3 of 15 Indoco Remedies Limited January 21, 2025 Now on the International Formulation business front, revenues from international business are at INR1,074 million compared to INR1,947 million for the same quarter last year, as has been explained by Aditi earlier.
- Regulated markets revenue was INR684 million in the third quarter of financial year 2025, compared with INR1,475 million in the same quarter last year.
Show source
Revenues from regulated markets for the quarter are at INR684 million as against INR1,475 million for the same quarter last year.
- API business revenue was INR28 million in the third quarter of financial year 2025, compared with INR33 million in the same quarter last year; AnaCipher CRO and Indoco Analytical Solutions services revenue was INR6 million, compared with INR8 million.
Show source
Revenues from API business for the quarter are at INR28 million against INR33 million; and from services, AnaCipher CRO and Indoco Analytical Solutions are at INR6 million against INR8 million.
- The company was incurring about INR6 crores to INR7 crores per quarter in fixed costs related to Florida Pharma, with certain portions recovered from sales.
Show source
But still, there is on an average, about INR6 crores to INR7 crores per quarter is the fixed cost, which currently we are incurring.
- EBITDA margin had declined from 18% and 20% to 15% last year and averaged 13% this year; after the quarter's results, it was about 10.5% or 11% on a 9-month basis.
Show source
Aditi Panandikar: So we've come down from EBITDA at the level of 18% and 20% to 15% last year, averaging 13% this year.
- The company attributed the quarter's results to a sales deficit of close to INR100 crores while fixed costs at its plants and sites remained unchanged.
Show source
So like I said in the opening, when you sort of have a deficit of close to INR100 crores in sales, but the fixed costs of the plants and sites stay the way they are, that has been the reason for this quarter.
- Cyclopam prescriptions grew by 23% in October and November 2024 compared with the same period last year; IQVIA classified Cyclopam among the top 100 brands growing fastest in prescription.
Show source
So October, November 2024 over same period last year, prescriptions of Cyclopam have grown by 23%.
- Rexidin-M prescriptions grew by 18.7% in October and November 2024 compared with the same period last year.
Show source
Rexidin-M, which is a dental product, prescriptions have grown by 18.7%.
- Sensodent-K prescriptions grew by 23% in October and November 2024 compared with the same period last year; the company took the product OTC through Warren Remedies.
Show source
Sensodent-K, which is actually we took OTC through Warren Remedies, the prescriptions have grown by 23%.
- Indoco Remedies' Cital and Cital-Uti together crossed INR100 crores MAT December.
Show source
Cital and Cital-Uti together have crossed INR100 crores MAT December.
- Indoco Remedies' tax rate is around 9% to 10% and can inch up.
Show source
Aditi Panandikar: We have been -- right now it is around 9% to 10%.
- Indoco Remedies' consolidated other expenses were INR165 crores this quarter, including expenses related to Warren, FPP and Indoco.
Show source
Pramod Ghorpade: While Vishal, when you talk about INR165 crores, that is at consolidated level, which includes certain expenses related to Warren, FPP and Indoco.
- Indoco Remedies' standalone other expenses averaged INR139 crores this quarter.
Show source
At Indoco stand-alone, if you see our average this quarter, we are at INR139 crores.
- Indoco Remedies' standalone other expenses are typically between INR120 crores and INR130 crores, but additional remediation costs brought them to INR140 crores at this point of time.
Show source
But because of certain additional costs related to remediation, we are at INR140 crores at this point of time.
- Indoco Remedies' consolidated other expenses are about INR150 crores, including around another INR20 crores for FPP and Warren.
Show source
So about INR150 crores.
- The company saw a sales drop from the reg market of close to INR90 crores in this quarter alone; it had orders of INR180 crores in hand, and the forgone sales could have been INR100 crores, with INR100 crores of additional revenues that could have been collected in this quarter.
Show source
So the largest impact has been seen only in this quarter, where INR100 crores additional revenues could have been collected.
- Indoco Remedies' margins were severely impacted this quarter only because of non-supply of product.
Show source
As I said, it was only because of non-supply of product in this quarter that the margins were so severely impacted.
- Indoco Remedies' India business performance has benefited from good strategies being properly implemented and improved sales effectiveness. Replaced by a later filing.
Show source
And this has come through both good strategies and good strategies being implemented properly as well as sales effectiveness improvement.
Money and capital
- The company incurred close to INR200 crores of capex in this year, including new machine upgradation, projects and advances.
Show source
Pramod Ghorpade: In this year, we have incurred close to about INR200 crores, including some new machines upgradation, all the projects, some advances.
What it expects ahead
What management expects
- The company expects Europe to grow close to 15% at least; the company said it was not giving much guidance.
Show source
But one would have to expect close to 15% at least.
- The company had been confident of maintaining an EBITDA margin close to 13% to 14% this year, but that expectation had been derailed by the quarter's results.
Show source
So we had said very clearly that this year, we were confident of maintaining close to 13% -- between 13% and 14%, but that has gone for a toss.
- The company expects to remain impacted for at least the next two quarters by warning letter related issues and sales to US from the sterile plant; management does not expect to return to 15% EBITDA margins before then, and could start seeing early signs of the 13% margin it was going at possibly by Q3 of next year.
Show source
But the 13% we were going at, possibly by Q3 of next year, we could start seeing some early signs of it.
- Under Indoco Remedies Limited's master manufacturing plan, cost per unit was expected to go down.
Show source
Going forward, as part of the master manufacturing plan, in any case, cost per unit was to go down.
- The company expected to start seeing some improvement on a geographical business basis in the fourth quarter.
Show source
So I see in the fourth quarter itself, we'll be able to see on geographical business basis, we'll start seeing some improvement for sure.
- The company expected improvement in per-head yield in its India business because it was not increasing the number of people.
Show source
Also in the India business, given that we are not increasing the number of people, we will also see an improvement in per head yield, PHY, that should help.
Show 4 more statements
What management expects
- The company said the effects of extra remediation costs might not be clearly visible over the next two quarters.
Show source
As you rightly said, in the next two quarters because of the extra cost on remediation, this impact we may not be able to see correctly.
- Indoco Remedies' remediation costs will continue for at least two quarters and will continue in a certain measure after that.
Show source
Aditi Panandikar: No, the remediation costs will continue for at least two quarters.
- The company expected certain costs, especially other expenses, to come under control through work to contain and check them. Replaced by a later filing.
Show source
And certain costs, especially of the -- like other expenses, where there is a lot of work being put in right now to sort of contain them, check, etcetera, those will come under control.
Orders
- Order book for international formulations business to Europe and US stood at about INR180 crores at the time of the call.
Show source
You'll be pleased to know that our order book for international formulations business to Europe and US today stands at about INR180 crores.
What it is building and selling
Projects and capacity
- At Indoco Remedies Limited's Plant II sterile plant, Line 1 was fully operational and had exported one terminally sterilized product to the US; Line 2 was operational and taking exhibit batches but had not been inspected by the FDA.
Show source
Sundeep Bambolkar: From the Plant II, that is a sterile plant, Line 1 is fully operational, and we have been exporting 1 terminally sterilized product to the US from that line.
- Sterile plant Line 3 was scheduled to be ready to go commercial by the first week of February, and Line 4 by the first week of March.
Show source
Line 3 will be ready by the first week of February to go commercial and Line 4 will be ready by first week of March.
Demand and pricing
- Indoco Remedies' prescriptions for Oxipod-CV are growing by 40%.
Show source
On Oxipod-CV, it is growing by 40%.
- Market shares had gained across most of its top brands, and the company was growing better than the covered market across most of those brands.
Show source
When one compares IRL, Indoco Remedies Limited, with the covered market, across most of the top brands, we are doing better than the covered market on growth, and our market shares have also seen a gain.
- Almost all of Indoco Remedies Limited's top brands, except ATM (azithromycin), were marginally in negative growth; ATM was doing better than its market.
Show source
Almost all our top brands, except for ATM, azithromycin, which is, in Page 2 of 15 Indoco Remedies Limited January 21, 2025 any case, doing better than its market, is marginally in negative.
- Indoco Remedies' Cloben-G and Azole product is the number one prescribed antifungal by ENTs.
Show source
Cloben-G and Azole product is number one prescribed antifungal by ENTs.
Show 4 more statements
Demand and pricing
- Indoco Remedies' Cital is the number one prescribed urinary alkalizer by urologists and GPs.
Show source
Cital is the number one prescribed urinary alkalizer by urologists and GPs.
- Indoco Remedies' Noxa is the number one prescribed newly launched ozenoxacin antifungal.
Show source
Your Ninaf -- Noxa is number one prescribed ozenoxacin antifungal -- new launched antifungal.
- Indoco Remedies' prescriptions for legacy products are growing at the same rate. Replaced by a later filing.
Show source
So the prescription growth is very much same.
- Indoco Remedies' new product Noxa has done exceedingly well. Replaced by a later filing.
Show source
On the new products also, if you look at products like Noxa, they have done exceedingly well.
Everything else said on the call
Other
- The company implemented SAP S/4HANA in less than 8 months, almost 2 years before the call, and won an award from SAP; the implementation was well settled and had made the organization very efficient.
Show source
The SAP S/4HANA implementation happened almost 2 years back, and we did it in record time of less than 8 months, and we won an award from the SAP.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Sajal Kapoor: No, that's helpful. And the implementation of SAP S/4HANA, that -- is that integration fully complete within the organization? And with that kind of an infrastructure back end and the digital initiatives that you spoke about, I mean, is it fair to assume that the efficiency and productivity will take a significant jump going ahead?
Answer, sundeep bambolkar
Sundeep Bambolkar: Yes, definitely. The SAP S/4HANA implementation happened almost 2 years back, and we did it in record time of less than 8 months, and we won an award from the SAP. So that is well settled, and that has made the entire organization very efficient.
Question
Okay. And lastly, on this Florida Pharma, I mean, how much is the -- so from simple perspective, I think our fixed costs have increased because we have acquired this front end in the US and we are kind of facing a near-term pain because of that increase in fixed cost and our output is not commensurate with that increase in fixed cost. So I'm just trying to understand what is that amount that we are bleeding? Is it INR10 crores, INR20 crores? What is that additional fixed cost that is currently hitting our P&L, but it's not giving us the output because of supply challenges?
Answer, pramod ghorpade
Pramod Ghorpade: Yes. So Sajal, I'll just take this question. FPP, though we are incurring certain additional spend there, but if you see from a revenue perspective, we have started generating revenue starting from day 1. That is on account of 2. One is about certain current -- the existing arrangements with third-party suppliers and sales from FPP, that is one. And secondly, our supplies, Indoco supplies to FPP. So that is helping us to cover up certain fixed costs.
Answer, pramod ghorpade
But still, there is on an average, about INR6 crores to INR7 crores per quarter is the fixed cost, which currently we are incurring. Certain portion we are recovering from sales.
Question
Sajal Kapoor: And do we expect this fixed cost of 7, 8 quarters -- INR7 crores, INR8 crores per quarter or, let's say, INR30 crores on an annualized basis, is it expected to go up maybe because of we plan to hire more people or salary increments, that kind of a thing?
Answer, aditi panandikar
Aditi Panandikar: No, no. So there are just 6 employees in FPP, and it is more of KOL management of generics. So there is no expectation to increase number of employees.
Question
Sajal Kapoor: Sure. And finally, ma'am, is it still kind of 60-40 ratio that we expect 60% to go through our own front end in the US and 40% would still be through partners?
Answer, aditi panandikar
Aditi Panandikar: Yes. So as I discussed already, we've just got the warning letter and our response -- initial response to the warning letter has gone off. And we have committed a certain time period in which we will be giving a more concrete plan. In the interim, we are constantly now in communication with the FDA to keep checking whether we can supply -- which products we can supply safely. We are also in constant touch with all our customers who are all auditing us to evaluate the risk in taking product from our site. Coming qualitatively to the issues in the plant, the team is looking at each of them in greater detail. And we have already hired remediation partners, and they're working with the team as we speak.
Question
And probably post that, it should come out.
Answer, aditi panandikar
Aditi Panandikar: Yes. That's a correct assumption. Rather than third, I think because it came towards the fag end of third quarter, I would expect it more to be in the fourth quarter this year and the first quarter of next year.
Question
Sudarshan Padmanabhan: Sure. And any idea what would be the quantum, ma'am?
Answer, aditi panandikar
Aditi Panandikar: Difficult to say at this stage as we are still evaluating the amount of work to be done.
Question
Sudarshan Padmanabhan: Sure. And just persisting a little bit more on the US I mean we also have certain interesting products like Combigan and brinzolamide, is there a way where we will continue to supply or is this an opportunity that we will still benefit from in FY '26?
Answer, aditi panandikar
Aditi Panandikar: So what we have done is, as in any business, once you see the risk, and it is not after this has happened, for some time now, we have recognized that we have only one site for sterile. And the company has started strategically working on creating other manufacturing locations from where we can source it, but it will take some time.
Question
Sudarshan Padmanabhan: Sure. And just moving on to European business. I mean, as you said, this quarter has various issues, but the order book looks good for the near term. Qualitatively, say FY '26, FY '27, I mean, I understand US is a little bit of a difficult project given that the regulatory issues have to get detangled. But how do we see Europe kind of driving growth in that side?
Answer, aditi panandikar
Aditi Panandikar: We are actually not giving much guidance, to be honest. But one would have to expect close to 15% at least.
Question
Sudarshan Padmanabhan: Sure. And with respect to the semi-regulated markets, I mean, what was the specific issue that we saw this quarter, ma'am?
Answer, aditi panandikar
Aditi Panandikar: No, semi-regulated is a typical model where we are actually selling our brands. So if you see the secondary performance, it is pretty constant. It is just because of the distributor model as and when they sort of give you orders and you get to sort of sell out, then you get the primaries. So as such, it is typically a business, which is very heavy in the four th quarter. We have got the team to start working on making it more predictable around the year.
Question
Sudarshan Padmanabhan: And also, spending a little time on taking cues from the previous participant on the cost side. I mean, this quarter or specifically the last few quarters, it has been a confluence of negative operating leverage and various costs. But say, if I'm saying the next 2 years or so, means our gross margin is good, which means that the majority of the impact is below the gross margin. So as we see the ramp-up, how do we see the margin expanding? I mean...
Answer, aditi panandikar
Aditi Panandikar: So we've come down from EBITDA at the level of 18% and 20% to 15% last year, averaging 13% this year. And with the shocker of this quarter, it has come down on -- for a 9-month basis down to, I think, 10.5% or 11%. So naturally, 1 quarter like that really puts you back a bit, quite Page 7 of 15 Indoco Remedies Limited January 21, 2025 a bit. So we had said very clearly that this year, we were confident of maintaining close to 13% -- between 13% and 14%, but that has gone for a toss. So now we'll have to work back slowly and steadily. But as you rightly said, fundamentally, there is nothing why we should -- I mean, we will not allow another such quarter where so many sort of headwinds hit us at one time.
Show 14 more questions
Question
Sudarshan Padmanabhan: Ma'am, can you talk a little bit more on the cost cutting strategy because, I mean, I understand that the business has come off. And we also are seeing some kind of escalation on the fixed cost. I mean that is from a longer-term perspective. But is there any kind of a fact you see in the system that has impact, which can kind of allay the kind of issues that you are seeing on the negative operating leverage...
Answer, aditi panandikar
Aditi Panandikar: Yes. So like I said in the opening, when you sort of have a deficit of close to INR100 crores in sales, but the fixed costs of the plants and sites stay the way they are, that has been the reason for this quarter. Going forward, as part of the master manufacturing plan, in any case, cost per unit was to go down. So I see in the fourth quarter itself, we'll be able to see on geographical business basis, we'll start seeing some improvement for sure. Also in the India business, given that we are not increasing the number of people, we will also see an improvement in per head yield, PHY, that should help. And certain costs, especially of the -- like other expenses, where there is a lot of work being put in right now to sort of contain them, check, etcetera, those will come under control. As you rightly said, in the next two quarters because of the extra cost on remediation, this impact we may not be able to see correctly.
Answer, aditi panandikar
But I think after such a quarter, we will, in future calls, try to give more data on operational efficiency that we are achieving at sites, yes.
Question
Sudarshan Padmanabhan: Sure. Ma'am, on the domestic business, I mean, since you've taken a lot of measures to improve the efficiency, digital as well as on the MR side, I mean, how do we see the prescription -- the penetration of our products? The kind of market share or the mind share that we are seeing? And if you can just elaborate it specifically with certain products, especially if you're talking about the top three products, how do we see that picking up? And also with respect to the new launches? I mean, how do we see the new launches also driving?
Answer, aditi panandikar
Aditi Panandikar: Yes. So just to give you a glimpse for -- because we get prescription data from outside sources is a bit delayed. So I can talk for the October, November period. So October, November 2024 over same period last year, prescriptions of Cyclopam have grown by 23%. And IQVIA has classified Cyclopam as one of in the top 100 brands growing fastest in prescription. Rexidin-M, which is a dental product, prescriptions have grown by 18.7%. Sensodent-K, which is actually we took OTC through Warren Remedies, the prescriptions have grown by 23%.
Answer, aditi panandikar
On Oxipod-CV, it is growing by 40%. So typically, if you see the prescription trend is across the legacy products, we are really concentrating on the fundamentals of the business. So the prescription growth is very much same. On the new products also, if you look at products like Noxa, they have done exceedingly well. Page 8 of 15 Indoco Remedies Limited January 21, 2025 And let me just try and give you some details. Cloben-G and Azole product is number one prescribed antifungal by ENTs. Cital is the number one prescribed urinary alkalizer by urologists and GPs.
Answer, aditi panandikar
Cital and Cital-Uti together have crossed INR100 crores MAT December. Your Ninaf -- Noxa is number one prescribed ozenoxacin antifungal -- new launched antifungal. So a lot of good happening in the India business. And this has come through both good strategies and good strategies being implemented properly as well as sales effectiveness improvement.
Question
Sudarshan Padmanabhan: One final question before I join back in the queue is now that we have certain losses, what is the kind of tax rate that we should be looking at?
Answer, aditi panandikar
Aditi Panandikar: And the losses are only for this quarter.
Answer, aditi panandikar
Aditi Panandikar: On YTD, we are still positive. So we will have to pay tax.
Answer, anush mokashi
Anush Mokashi: Okay. And next question was about the margins. So given as compared to peers, we are at a bit lower side. And I'm assuming that is because of some lower chronic mix. And I heard you saying that you want to increase the chronic mix going ahead. So any guidance on what our target number you're looking about chronic mix going ahead? Page 9 of 15 Indoco Remedies Limited January 21, 2025 Aditi Panandikar: No. So the sales may not be lower because of the chronic mix.
Answer, aditi panandikar
But we have always grown India business in a stealthy fashion. So I really didn't get your question. Are you saying that because we don't have chronic, we are lower in size. Is that your question?
Answer, anush mokashi
Anush Mokashi: No, I'm actually assessing the impact on margins. Maybe I'm missaying that ?
Answer, aditi panandikar
Aditi Panandikar: No, on margins, whether it's chronic or acute, in fact, legacy products are much better on margin because the brand is far more established in the market.
Answer, aditi panandikar
Aditi Panandikar: We have been -- right now it is around 9% to 10%. It can inch up. But when the other side also is growing rampantly, it would not be correct to talk of increase in contribution from chronic, okay?
Question
Vishal Manchanda: So are these products already approved for you and whether you own the dossier or Clarity Pharma would own?
Answer, aditi panandikar
Aditi Panandikar: No, no, no. We have the dossiers. Over the last 20 years, we inched up from being pure contract manufacturers to eventually owning the IP to eventually owning the dossiers and MFs, okay? It's only that we weren't supplying to others. So now we supply to Clarity, which is our partner. So we have a state, yes.
Answer, sundeep bambolkar
Sundeep Bambolkar: Clarity will be only a distribution partner.
Question
Vishal Manchanda: And any sense on what revenue can this generate, maybe a range, if not a number?
Answer, aditi panandikar
Aditi Panandikar: No, we are not giving out numbers at this stage.
Question
Vishal Manchanda: Okay. Okay. And second, on the US, the new lines that have been refurbished. I just wanted to understand what was the need to refurbish the lines? Whether these lines were kind of obsolete and that led you to refurbish? Or was it for compliance reasons? Page 10 of 15 Indoco Remedies Limited January 21, 2025 Aditi Panandikar: Yes, compliance.
Answer, aditi panandikar
So we had audits last February and then this July. So the last February audits were initially when we gave responses, where we got the OAI. In those responses, we committed to -- so there were some on sterility -- sterile practices as in how the workers moved inside because of lack of space in areas, etcetera, such things were identified. Also certain improvements towards sterility like glove ports and going for isolators, larger LAFs, those commitments we made and, therefore, the refurbishments.
Question
Vishal Manchanda: Okay. So you would have replaced the entire line in that case. And the old line has been removed from the space?
Answer, aditi panandikar
Aditi Panandikar: No, we have not replaced the line. We have not replaced the line. We have refurbished the area and sort of upgraded the lines wherever required.
Question
Vishal Manchanda: Okay. And the total capex that we would have incurred for this?
Answer, pramod ghorpade
Pramod Ghorpade: In this year, we have incurred close to about INR200 crores, including some new machines upgradation, all the projects, some advances.
Question
Vishal Manchanda: And specifically for this refurbishment project?
Answer, aditi panandikar
Aditi Panandikar: Sorry, Vishal, just to give you more clarity. For the line upgradation, it was more of a repairs and maintenance cost. So it is not entirely capex. Certain -- of course, certain components we got, which is a part of capex.
Question
Vishal Manchanda: Okay. And just one final one. The other expenses line is quite elevated this quarter, around INR165 crores. I think about 15% jump and probably the highest ever we have seen. So any details there?
Answer, aditi panandikar
Aditi Panandikar: So some amount of remediation costs have started coming in. There was also, I think, a good amount of payout on incentives for India business. And as Pramod correctly said, repairs and maintenance has absorbed a lot of the remediation for the lines in plant 2.
Answer, pramod ghorpade
Pramod Ghorpade: While Vishal, when you talk about INR165 crores, that is at consolidated level, which includes certain expenses related to Warren, FPP and Indoco. At Indoco stand-alone, if you see our average this quarter, we are at INR139 crores. So -- which we had indicated. Like our average is between INR120 crores to INR130 crores. But because of certain additional costs related to remediation, we are at INR140 crores at this point of time.
Question
Vishal Manchanda: Okay. Okay. And we -- like how should we expect this to be in the future, the other expense line, around INR150 crores, INR140 crores or INR150 crores levels?
Answer, pramod ghorpade
Pramod Ghorpade: No, no, no. Certainly, you will have a range of about INR120 crores to INR130 crores.
Question
Vishal Manchanda: At a consolidated level, I mean?
Answer, pramod ghorpade
Pramod Ghorpade: Consolidation level adds around another INR20 crores for other two entities, FPP and Warren. So about INR150 crores. Page 11 of 15 Indoco Remedies Limited January 21, 2025 Moderator: The next question is from the line of Narendra from RoboCapital.
Answer, aditi panandikar
Aditi Panandikar: So we are, at this time, as I said earlier, we are in communication with FDA to find out what we can and cannot supply with zero risk, some risk, etcetera, and we're also talking to our customers. So sterile products are basically of two kinds, aseptic filling and terminal sterilized. Terminally sterilized products have very low risk because they are sterilized at the end. So we are going ahead manufacturing and supplying those products, but they form a very small percentage of our portfolio. So we are still waiting for okay to start manufacturing the aseptically filled products. Since our outline response has gone to FDA, we have to give them some time before they come back to us and we can start getting clarifications from there on. Narendra: Okay.
Answer, aditi panandikar
Aditi Panandikar: Yes. So I think in the beginning, we spoke of this that a couple of our sites where the master manufacturing plan is being rolled out, there were delays in certain completion of projects because of which supply from those sites got impacted. That's it. Narendra: Okay. So going ahead from FY '26 onwards, except Europe -- except US, all of our geographies should go back to the earlier levels of performance, right?
Answer, aditi panandikar
Aditi Panandikar: No, it would be very difficult for us to give you that, and we are anyway not giving out that ki nd of data. But your question is correct. As I said, it was only because of non-supply of product in this quarter that the margins were so severely impacted. Narendra: Okay. Okay. Understood. And on the capex, which you have done, I can see around INR400- odd crores in the past 2 years.
Question
I mean, if I was to kind of understand when do we move back with all your issues with remediation, with all the issues with supply into the existing markets. If I was to look at the next four quarters, say, Q4 -- upcoming Q4 and then Q1, Q2, Q3 of the next year, when do we think we kind of will move back to business as usual and maybe like touch 15% EBITDA margins in this time period?
Answer, aditi panandikar
Aditi Panandikar: So as I said, the next two quarters, we will stay impacted at least for the warning letter related issues and sales to US from the sterile plant. So nothing before that, I don't expect we will be able to come back to 15% for sure. But the 13% we were going at, possibly by Q3 of next year, we could start seeing some early signs of it.
Question
Ankit Minocha: Right. And finally, these remediation costs, which are kind of coming up extensively, do these costs now start to taper out slightly and reduce slightly?
Answer, aditi panandikar
Aditi Panandikar: No, the remediation costs will continue for at least two quarters. And after that also in a certain measure.
Answer, aditi panandikar
Aditi Panandikar: So as we said, in this quarter alone, we have not -- we have seen a sales drop from the reg market of close to INR90 crores. And I said in the beginning that we have orders of INR180 crores in hand. So that INR90 crores could have easily gone to INR100 crores. So the largest impact has been seen only in this quarter, where INR100 crores additional revenues could have been collected.
Questions about this call
- When was the Indoco Remedies Q3 FY25 earnings call transcript filed?
- Indoco Remedies filed the transcript with the exchange on 24 Jan 2025. This page is built from that transcript.
- What does this page list?
- 47 statements from the transcript across 7 topics, 22 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 24 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.